Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.

Conclusions: Elbasvir/grazoprevir for 12 weeks was safe and highly effective in participants aged ≤35 years with hepatitis C virus genotype 1 or 4 infection. PMID: 32459122 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32459122?dopt=Abstract

Source: Current Medical Research and Opinion - May 28, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research